Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7430428 | 0.73 | CYP1A2 (1.00) | SMN1; SMN2CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL10118317 | 0.73 | CYP1A2 (0.79) | SMN1; SMN2CYP1A2CYP3A4CYP2D6BLM | |
| Hydrochloric Acid SCHEMBL29651387 | 0.72 | BLM (1.00) | SMN1; SMN2CYP1A2CYP3A4CYP2D6BLM | |
| Hydrochloric Acid SCHEMBL7194533 | 0.72 | BLM (1.00) | SMN1; SMN2CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL9813064 | 0.70 | CYP1A2 (0.74) | SMN1; SMN2CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL8199403 | 0.70 | PPARG (0.47) | LMNASMN1; SMN2GAATSHRKDM4E | |
| SCHEMBL6575575 | 0.69 | CYP1A2 (0.83) | SMN1; SMN2CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL18239557 | 0.69 | CYP3A4 (0.90) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16641094 | 0.69 | CYP19A1 (0.77) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL31157848 | 0.69 | CYP19A1 (0.77) | CYP1A2CYP3A4CYP2D6BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142353-A1 | ANTIBACTERIAL COMPOUNDS | ABBVIE INC. | 2007-06-21 | — | — | US | claimed |
| US-7196200-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2007-03-27 | — | — | US | claimed |
| US-20050159423-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | claimed |
| US-7737159-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070142353-A1 | ANTIBACTERIAL COMPOUNDS | ABBVIE INC. | 2007-06-21 | — | — | US | disclosed |
| US-7196200-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050159423-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142353-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, FDPS, PGLS | LMNA 3464/4885SMN1; SMN2 4141/4885CYP1A2 1523/4885 |
| US-20050159423-A1 | Antibacterial compounds | MRPL21, FDPS, PGLS | LMNA 3464/4885SMN1; SMN2 4141/4885CYP1A2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.